Mishra Gauravi A, Pimple Sharmila A, Shastri Surendra S
Department of Preventive Oncology, Tata Memorial Hospital, Mumbai, India.
Oncology. 2016;91 Suppl 1:1-7. doi: 10.1159/000447575. Epub 2016 Jul 28.
Cervical cancer is the fourth most common cancer among women globally and the second most common cancer among Indian women. India alone bears 23% of the global cervical cancer burden. In India, population-based cervical cancer screening is largely nonexistent in most regions due to competing healthcare priorities, insufficient financial resources and a limited number of trained providers. Hence, most of the cases present in advanced stages of the disease, thus leading to increased mortality and reduced survival. Various screening options like cytology, visual-based screening and testing for high-risk HPV are available. Several cross-sectional studies have looked at the comparative efficacy of different screening tests. Three important randomized controlled trials from India have shown the efficacy of screening once in a life time with HPV DNA, one-time screening with VIA by trained nurses and four-time screening with VIA by trained primary health workers, reducing mortality due to cervical cancers. Prevention of cervical cancers with two-dose HPV vaccination and early detection of precancerous cervical lesions of the eligible population through screening and their appropriate treatment with a single-visit 'screen-and-treat' approach appear to be promising for low-middle-income countries including India.
宫颈癌是全球女性中第四大常见癌症,在印度女性中则是第二大常见癌症。仅印度一国就承担了全球23%的宫颈癌负担。在印度,由于医疗保健重点相互竞争、财政资源不足以及受过培训的医疗人员数量有限,大多数地区基本不存在基于人群的宫颈癌筛查。因此,大多数病例在疾病晚期才出现,从而导致死亡率上升和生存率降低。有多种筛查方法可供选择,如细胞学检查、基于视觉的筛查以及高危型人乳头瘤病毒检测。多项横断面研究探讨了不同筛查测试的相对疗效。印度的三项重要随机对照试验表明,终身进行一次人乳头瘤病毒DNA筛查、由经过培训的护士进行一次醋酸肉眼观察法(VIA)筛查以及由经过培训的初级卫生工作者进行四次醋酸肉眼观察法筛查均具有疗效,可降低宫颈癌死亡率。对于包括印度在内的中低收入国家而言,通过两剂人乳头瘤病毒疫苗接种预防宫颈癌,以及通过筛查对符合条件的人群早期发现宫颈癌前病变,并采用单次就诊的“筛查即治疗”方法进行适当治疗,似乎前景广阔。